Dr. Elie G. Dib
Claim this profileGenesys Hurley Cancer Institute
Area of expertise
Cancer
Elie G. Dib has run 7 trials for Cancer. Some of their research focus areas include:
Multiple Myeloma
Elie G. Dib has run 6 trials for Multiple Myeloma. Some of their research focus areas include:
Affiliated Hospitals
Genesys Hurley Cancer Institute
Saint Joseph Mercy Hospital
Clinical Trials Elie G. Dib is currently running
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting
2 awards
Phase 3
19 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
More about Elie G. Dib
Clinical Trial Related
7 years of experience running clinical trials · Led 38 trials as a Principal Investigator · 18 Active Clinical Trials
Treatments Elie G. Dib has experience with
- Nivolumab
- Lenalidomide
- Dexamethasone
- Atezolizumab
- Durvalumab
- Pembrolizumab
Breakdown of trials Elie G. Dib has run
Cancer
Multiple Myeloma
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Elie G. Dib specialize in?
Elie G. Dib focuses on Cancer and Multiple Myeloma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Elie G. Dib currently recruiting for clinical trials?
Yes, Elie G. Dib is currently recruiting for 18 clinical trials in Flint Michigan. If you're interested in participating, you should apply.
Are there any treatments that Elie G. Dib has studied deeply?
Yes, Elie G. Dib has studied treatments such as Nivolumab, Lenalidomide, Dexamethasone.
What is the best way to schedule an appointment with Elie G. Dib?
Apply for one of the trials that Elie G. Dib is conducting.
What is the office address of Elie G. Dib?
The office of Elie G. Dib is located at: Genesys Hurley Cancer Institute, Flint, Michigan 48503 United States. This is the address for their practice at the Genesys Hurley Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.